Physiologically-based modelling in mice suggests an aggravated loss of clearance capacity after toxic liver damage

被引:49
作者
Schenk, Arne [1 ]
Ghallab, Ahmed [2 ,3 ]
Hofmann, Ute [4 ,5 ]
Hassan, Reham [2 ,3 ]
Schwarz, Michael [6 ]
Schuppert, Andreas [1 ,7 ]
Schwen, Lars Ole [8 ]
Braeuning, Albert [6 ]
Teutonico, Donato [7 ,9 ]
Hengstler, Jan G. [2 ]
Kuepfer, Lars [7 ]
机构
[1] Rhein Westfal TH Aachen, Joint Res Ctr Computat Biomed, Aachen, Germany
[2] Tech Univ Dortmund, Leibniz Res Ctr Working Environm & Human Factors, Dortmund, Germany
[3] South Valley Univ, Dept Forens Med & Toxicol, Fac Vet Med, Qena, Egypt
[4] Dr Margarete Fischer Bosch Inst Clin Pharmacol, Stuttgart, Germany
[5] Univ Tubingen, Stuttgart, Germany
[6] German Fed Inst Risk Assessment, Dept Food Safety, Berlin, Germany
[7] Bayer AG, Syst Pharmacol, Leverkusen, Germany
[8] Fraunhofer MEVIS, Bremen, Germany
[9] Inst Rech Int Servier, Clin PK & Pharmacometr, Suresnes, France
关键词
CLINICAL PHARMACOKINETICS; METABOLISM; EXPRESSION; PRAVASTATIN; PARAMETERS; CAFFEINE; ZONATION; SYSTEM; MOUSE;
D O I
10.1038/s41598-017-04574-z
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Diseases and toxins may lead to death of active liver tissue, resulting in a loss of total clearance capacity at the whole-body level. However, it remains difficult to study, whether the loss of metabolizing tissue is sufficient to explain loss of metabolic capacity of the liver or whether the surviving tissue undergoes an adaptive response to compensate the loss. To understand the cellular impact of toxic liver damage in an in vivo situation, we here used physiologically-based pharmacokinetic modelling to investigate pharmacokinetics of a specifically designed drug cocktail at three different sampling sites of the body in healthy mice and mice treated with carbon tetrachloride (CCl4). Liver zonation was explicitly quantified in the models through immunostaining of cytochrome P450s enzymes. Comparative analyses between the simulated decrease in clearance capacity and the experimentally measured loss in tissue volume indicated that CCl4-induced impairment of metabolic functions goes beyond the mere loss of metabolically active tissue. The here established integrative modelling strategy hence provides mechanistic insights into functional consequences of toxic liver damage in an in vivo situation, which would not have been accessible by conventional methods.
引用
收藏
页数:13
相关论文
共 32 条
[1]   Characterization of primary human hepatocyte spheroids as a model system for drug-induced liver injury, liver function and disease [J].
Bell, Catherine C. ;
Hendriks, Delilah F. G. ;
Moro, Sabrina M. L. ;
Ellis, Ewa ;
Walsh, Joanne ;
Renblom, Anna ;
Puigvert, Lisa Fredriksson ;
Dankers, Anita C. A. ;
Jacobs, Frank ;
Snoeys, Jan ;
Sison-Young, Rowena L. ;
Jenkins, Rosalind E. ;
Nordling, Asa ;
Mkrtchian, Souren ;
Park, B. Kevin ;
Kitteringham, Neil R. ;
Goldring, Christopher E. P. ;
Lauschke, Volker M. ;
Ingelman-Sundberg, Magnus .
SCIENTIFIC REPORTS, 2016, 6
[2]   INTERSPECIES COMPARISON OF INVIVO CAFFEINE PHARMACOKINETICS IN MAN, MONKEY, RABBIT, RAT, AND MOUSE [J].
BONATI, M ;
LATINI, R ;
TOGNONI, G ;
YOUNG, JF ;
GARATTINI, S .
DRUG METABOLISM REVIEWS, 1985, 15 (07) :1355-1383
[3]   Role of CYP1A2 in caffeine pharmacokinetics and metabolism: Studies using mice deficient in CYP1A2 [J].
Buters, JTM ;
Tang, BK ;
Pineau, T ;
Gelboin, HV ;
Kimura, S ;
Gonzalez, FJ .
PHARMACOGENETICS, 1996, 6 (04) :291-296
[4]   PHYSIOLOGICAL-PARAMETERS IN LABORATORY-ANIMALS AND HUMANS [J].
DAVIES, B ;
MORRIS, T .
PHARMACEUTICAL RESEARCH, 1993, 10 (07) :1093-1095
[5]  
EVERETT DW, 1991, DRUG METAB DISPOS, V19, P740
[6]   METABOLIC ZONATION OF THE LIVER - REGULATION AND IMPLICATIONS FOR LIVER-FUNCTION [J].
GEBHARDT, R .
PHARMACOLOGY & THERAPEUTICS, 1992, 53 (03) :275-354
[7]   Model-guided identification of a therapeutic strategy to reduce hyperammonemia in liver diseases [J].
Ghallab, Ahmed ;
Celliere, Geraldine ;
Henkel, Sebastian G. ;
Driesch, Dominik ;
Hoehme, Stefan ;
Hofmann, Ute ;
Zellmer, Sebastian ;
Godoy, Patricio ;
Sachinidis, Agapios ;
Blaszkewicz, Meinolf ;
Reif, Raymond ;
Marchan, Rosemarie ;
Kuepfer, Lars ;
Haeussinger, Dieter ;
Drasdo, Dirk ;
Gebhardt, Rolf ;
Hengstler, Jan G. .
JOURNAL OF HEPATOLOGY, 2016, 64 (04) :860-871
[8]   Expression of the human CYP3A4 gene in the small intestine of transgenic mice:: In vitro metabolism and pharmacokinetics of midazolam [J].
Granvil, CP ;
Yu, AM ;
Elizondo, G ;
Akiyama, TE ;
Cheung, C ;
Feigenbaum, L ;
Krausz, KW ;
Gonzalez, FJ .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :548-558
[9]   Clinical pharmacokinetics of pravastatin - Mechanisms of pharmacokinetic events [J].
Hatanaka, T .
CLINICAL PHARMACOKINETICS, 2000, 39 (06) :397-412
[10]   Modelling and PBPK Simulation in Drug Discovery [J].
Jones, Hannah M. ;
Gardner, Iain B. ;
Watson, Kenny J. .
AAPS JOURNAL, 2009, 11 (01) :155-166